# Elixiron Immunotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/elixiron-immunotherapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.elixiron.com
- Total disclosed funding: $27M
- Latest round: Series A (Aug 16, 2021)
- Investors on record: 7

## About

Established in 2017 and based in Shanghai, China, Elixiron Immunotherapeutics is dedicated to addressing unmet clinical needs through the development of novel immunotherapeutic drugs. The company was founded by Dr. Hongkai Chen and is led by CEO Ms. Xiaohua Duan. With a focus on advancing therapies for conditions such as vitiligo and Alzheimer's disease, Elixiron has established partnerships with global entities to enhance its research and development capabilities. The company has been recognized for its innovative efforts, receiving orphan drug designations from the U.S. FDA for its products targeting Hemophagocytic Lymphohistiocytosis (HLH) and Idiopathic Pulmonary Fibrosis (IPF). In March 2024, it closed a round of approximately CNY 100 million strategic investment.

The company's product pipeline includes EI-001, an IFN? antibody currently in Phase 1b/2 clinical development for the treatment of vitiligo, and EI-1071, a CSF-1R targeted small molecule drug in Phase 2 clinical trials aimed at treating Alzheimer's disease. The company's services are centered around the research, development, and clinical advancement of these innovative immunotherapeutic agents, with the goal of providing new treatment options for patients suffering from autoimmune and neurodegenerative disorders.

The company will use the strategic investment raised in March 2024 to expedite the clinical development of its key projects, expand its R&D capabilities, and seek further global partnerships to enhance its innovative immunotherapy portfolio.

## Funding rounds

- Series A, Aug 16, 2021, $27M — Daiwa Corporate Investment, Fubon Financial Holding, Mega International Commercial Bank, CDIB Capital Group, Pangu Capital, Taiwania Capital, Hong Tai Electric Industrial Co. Ltd.

## Investors

- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series A
- Fubon Financial Holding — Series A
- Mega International Commercial Bank — Series A
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series A
- Pangu Capital — Series A
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series A
- Hong Tai Electric Industrial Co. Ltd. — Series A